Literature DB >> 32561640

The guanine nucleotide exchange factor VAV3 participates in ERBB4-mediated cancer cell migration.

Veera K Ojala1,2,3, Anna M Knittle1, Peppi Kirjalainen1,2, Johannes A M Merilahti1,2,3, Maarit Kortesoja1, Denis Tvorogov1, Katri Vaparanta1,2,3, Shujun Lin4, Jürgen Kast4, Arto T Pulliainen1, Kari J Kurppa1, Klaus Elenius5,2,6.   

Abstract

ERBB4 is a member of the epidermal growth factor receptor (EGFR)/ERBB subfamily of receptor tyrosine kinases that regulates cellular processes including proliferation, migration, and survival. ERBB4 signaling is involved in embryogenesis and homeostasis of healthy adult tissues, but also in human pathologies such as cancer, neurological disorders, and cardiovascular diseases. Here, an MS-based analysis revealed the Vav guanine nucleotide exchange factor 3 (VAV3), an activator of Rho family GTPases, as a critical ERBB4-interacting protein in breast cancer cells. We confirmed the ERBB4-VAV3 interaction by targeted MS and coimmunoprecipitation experiments and further defined it by demonstrating that kinase activity and Tyr-1022 and Tyr-1162 of ERBB4, as well as the intact phosphotyrosine-interacting SH2 domain of VAV3, are necessary for this interaction. We found that ERBB4 stimulates tyrosine phosphorylation of the VAV3 activation domain, known to be required for guanine nucleotide exchange factor (GEF) activity of VAV proteins. In addition to VAV3, the other members of the VAV family, VAV1 and VAV2, also coprecipitated with ERBB4. Analyses of the effects of overexpression of dominant-negative VAV3 constructs or shRNA-mediated down-regulation of VAV3 expression in breast cancer cells indicated that active VAV3 is involved in ERBB4-stimulated cell migration. These results define the VAV GEFs as effectors of ERBB4 activity in a signaling pathway relevant for cancer cell migration.
© 2020 Ojala et al.

Entities:  

Keywords:  ERBB4; HER4; Vav guanine nucleotide exchange factor 3 (VAV3); breast cancer; cancer; cell migration; guanine nucleotide exchange factor (GEF); phosphotyrosine signaling; protein-protein interaction; receptor tyrosine kinase

Mesh:

Substances:

Year:  2020        PMID: 32561640      PMCID: PMC7450113          DOI: 10.1074/jbc.RA119.010925

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase.

Authors:  K Elenius; C J Choi; S Paul; E Santiestevan; E Nishi; M Klagsbrun
Journal:  Oncogene       Date:  1999-04-22       Impact factor: 9.867

Review 2.  The ERBB network: at last, cancer therapy meets systems biology.

Authors:  Yosef Yarden; Gur Pines
Journal:  Nat Rev Cancer       Date:  2012-07-12       Impact factor: 60.716

3.  ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional repression.

Authors:  Bryan Linggi; Graham Carpenter
Journal:  J Biol Chem       Date:  2006-06-30       Impact factor: 5.157

4.  ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer.

Authors:  Christopher P Mill; Michael D Zordan; S Michael Rothenberg; Jeffrey Settleman; James F Leary; David J Riese
Journal:  Genes Cancer       Date:  2011-08

5.  Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.

Authors:  Jonathan W Haskins; Don X Nguyen; David F Stern
Journal:  Sci Signal       Date:  2014-12-09       Impact factor: 8.192

6.  System-wide investigation of ErbB4 reveals 19 sites of Tyr phosphorylation that are unusually selective in their recruitment properties.

Authors:  Alexis Kaushansky; Andrew Gordus; Bogdan A Budnik; William S Lane; John Rush; Gavin MacBeath
Journal:  Chem Biol       Date:  2008-08-25

7.  Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2.

Authors:  K Zhang; J Sun; N Liu; D Wen; D Chang; A Thomason; S K Yoshinaga
Journal:  J Biol Chem       Date:  1996-02-16       Impact factor: 5.157

8.  The PRIDE database and related tools and resources in 2019: improving support for quantification data.

Authors:  Yasset Perez-Riverol; Attila Csordas; Jingwen Bai; Manuel Bernal-Llinares; Suresh Hewapathirana; Deepti J Kundu; Avinash Inuganti; Johannes Griss; Gerhard Mayer; Martin Eisenacher; Enrique Pérez; Julian Uszkoreit; Julianus Pfeuffer; Timo Sachsenberg; Sule Yilmaz; Shivani Tiwary; Jürgen Cox; Enrique Audain; Mathias Walzer; Andrew F Jarnuczak; Tobias Ternent; Alvis Brazma; Juan Antonio Vizcaíno
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

9.  Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer.

Authors:  Kiwon Lee; Yin Liu; Jun Qin Mo; Jinsong Zhang; Zhongyun Dong; Shan Lu
Journal:  BMC Cancer       Date:  2008-06-02       Impact factor: 4.430

Review 10.  A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.

Authors:  Helmout Modjtahedi; Byoung Chul Cho; Martin C Michel; Flavio Solca
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-03-19       Impact factor: 3.000

View more
  3 in total

1.  Role of Transportome in the Gills of Chinese Mitten Crabs in Response to Salinity Change: A Meta-Analysis of RNA-Seq Datasets.

Authors:  Adeel Malik; Chang-Bae Kim
Journal:  Biology (Basel)       Date:  2021-01-08

2.  Identification of the Novel Tumor Suppressor Role of FOCAD/miR-491-5p to Inhibit Cancer Stemness, Drug Resistance and Metastasis via Regulating RABIF/MMP Signaling in Triple Negative Breast Cancer.

Authors:  Wei-Chieh Huang; Hsiang-Cheng Chi; Shiao-Lin Tung; Po-Ming Chen; Ya-Chi Shih; Yi-Ching Huang; Pei-Yi Chu
Journal:  Cells       Date:  2021-09-24       Impact factor: 6.600

3.  Vav2 is a novel APP-interacting protein that regulates APP protein level.

Authors:  Youjia Zhang; Xiaxin Yang; Yongrui Liu; Liang Ge; Jiarong Wang; Xiulian Sun; Bo Wu; Junfeng Wang
Journal:  Sci Rep       Date:  2022-07-26       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.